BUY12XBI@$153.22

Notional

$1,838.66

Order type

Market order

Topping up XBI from 6.4% to 8.0% of book, the target weight. The editing sleeve is structurally starved: NTLA is the only tradeable CRISPR pure-play here, so BEAM, CRSP, EDIT, VERV and SANA are only reachable through the basket. Screened two newly surfaced gene-therapy names today and rejected both on the balance sheet: OCGN carries a $337M market cap against $1.5M of revenue, and both it and NVAX show negative book equity. Pre-revenue editing companies fail by dilution as often as by data, so the diversified vehicle is the correct way to hold that tier.